Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis
- PMID: 31215027
- PMCID: PMC6771956
- DOI: 10.1002/jcp.28947
Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis
Abstract
Multiple myeloma (MM) is a common hematologic malignancy for which the underlying molecular mechanisms remain largely unclear. This study aimed to elucidate key candidate genes and pathways in MM by integrated bioinformatics analysis. Expression profiles GSE6477 and GSE47552 were obtained from the Gene Expression Omnibus database, and differentially expressed genes (DEGs) with p < .05 and [logFC] > 1 were identified. Functional enrichment, protein-protein interaction network construction and survival analyses were then performed. First, 51 upregulated and 78 downregulated DEGs shared between the two GSE datasets were identified. Second, functional enrichment analysis showed that these DEGs are mainly involved in the B cell receptor signaling pathway, hematopoietic cell lineage, and NF-kappa B pathway. Moreover, interrelation analysis of immune system processes showed enrichment of the downregulated DEGs mainly in B cell differentiation, positive regulation of monocyte chemotaxis and positive regulation of T cell proliferation. Finally, the correlation between DEG expression and survival in MM was evaluated using the PrognoScan database. In conclusion, we identified key candidate genes that affect the outcomes of patients with MM, and these genes might serve as potential therapeutic targets.
Keywords: bioinformatics analysis; immune-associated genes; multiple myeloma; prognosis.
© 2019 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc.
Conflict of interest statement
The authors declare that there is no conflict of interests.
Figures







Similar articles
-
Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis.Int J Hematol. 2017 Jul;106(1):99-107. doi: 10.1007/s12185-017-2216-2. Epub 2017 Mar 18. Int J Hematol. 2017. PMID: 28316065
-
Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis.Int J Med Sci. 2020 Jul 25;17(14):2063-2076. doi: 10.7150/ijms.48244. eCollection 2020. Int J Med Sci. 2020. PMID: 32922167 Free PMC article.
-
Identification of key genes and pathways of thyroid cancer by integrated bioinformatics analysis.J Cell Physiol. 2019 Dec;234(12):23647-23657. doi: 10.1002/jcp.28932. Epub 2019 Jun 6. J Cell Physiol. 2019. PMID: 31169306
-
Gene Expression Profiles in Myeloma: Ready for the Real World?Clin Cancer Res. 2016 Nov 15;22(22):5434-5442. doi: 10.1158/1078-0432.CCR-16-0867. Clin Cancer Res. 2016. PMID: 28151711 Free PMC article. Review.
-
Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling.Semin Hematol. 2003 Oct;40(4):308-20. doi: 10.1016/s0037-1963(03)00197-5. Semin Hematol. 2003. PMID: 14582081 Review.
Cited by
-
Genes That Predict Poor Prognosis in Breast Cancer via Bioinformatical Analysis.Biomed Res Int. 2021 Apr 17;2021:6649660. doi: 10.1155/2021/6649660. eCollection 2021. Biomed Res Int. 2021. PMID: 33959662 Free PMC article.
-
Machine Learning-based Prediction of HBV-related Hepatocellular Carcinoma and Detection of Key Candidate Biomarkers.Medeni Med J. 2022 Sep 21;37(3):255-263. doi: 10.4274/MMJ.galenos.2022.39049. Medeni Med J. 2022. PMID: 36128800 Free PMC article.
-
Bio-informatics and in Vitro Experiments Reveal the Mechanism of Schisandrin A Against MDA-MB-231 cells.Bioengineered. 2021 Dec;12(1):7678-7693. doi: 10.1080/21655979.2021.1982307. Bioengineered. 2021. PMID: 34550868 Free PMC article.
-
Identification of Potential Prognostic Biomarker for Predicting Survival in Multiple Myeloma Using Bioinformatics Analysis and Experiments.Front Genet. 2021 Sep 10;12:722132. doi: 10.3389/fgene.2021.722132. eCollection 2021. Front Genet. 2021. PMID: 34567073 Free PMC article.
-
Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma.Explor Target Antitumor Ther. 2021;2(1):65-106. doi: 10.37349/etat.2021.00034. Epub 2021 Feb 28. Explor Target Antitumor Ther. 2021. PMID: 36046090 Free PMC article. Review.
References
-
- Adams, J. (2004). The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 5(5), 417–421. - PubMed
-
- Aouali, N. , Palissot, V. , El‐Khoury, V. , Moussay, E. , Janji, B. , Pierson, S. , … Berchem, G. (2009). Peroxisome proliferator‐activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells. British Journal of Haematology, 147(5), 662–671. 10.1111/j.1365-2141.2009.07902.x - DOI - PubMed
-
- Arana, P. , Paiva, B. , Cedena, M. T. , Puig, N. , Cordon, L. , Vidriales, M. B. , … San Miguel, J. F. (2018). Prognostic value of antigen expression in multiple myeloma: A PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia, 32(4), 971–978. 10.1038/leu.2017.320 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical